Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma

Recently, overexpression of the fibroblast growth factor receptor 3 (FGFR3) splice variants FGFR3‐IIIb and FGFR3‐IIIc was found in ~50% of hepatocellular carcinoma (HCC). Here, we aim to identify FGFR3‐IIIb/IIIc ligands, which drive the progression of HCC.

[1]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[2]  M. Kudo,et al.  Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. , 2018, Cancer treatment reviews.

[3]  A. Zell,et al.  Mesenchyme-derived factors enhance preneoplastic growth by non-genotoxic carcinogens in rat liver , 2017, Archives of Toxicology.

[4]  M. Mohammadi,et al.  Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. , 2017, Structure.

[5]  Hua Liang,et al.  miR-187 inhibits the growth of cervical cancer cells by targeting FGF9 , 2017, Oncology reports.

[6]  C. la Vecchia,et al.  Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.

[7]  Jun Chen,et al.  Mutation Detection of Fibroblast Growth Factor Receptor 3 for Infiltrative Hepatocellular Carcinoma by Whole-Exome Sequencing , 2017, Digestive Diseases and Sciences.

[8]  G. Guo,et al.  Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors , 2016, BioMed research international.

[9]  W. Qiu,et al.  Phenotypic and Signaling Consequences of a Novel Aberrantly Spliced Transcript FGF Receptor-3 in Hepatocellular Carcinoma. , 2016, Cancer research.

[10]  Chuanli Ren,et al.  The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer , 2016, Oncotarget.

[11]  R. Grose,et al.  Dysregulated FGF signalling in neoplastic disorders. , 2016, Seminars in cell & developmental biology.

[12]  K. O'Byrne,et al.  Targeting the fibroblast growth factor receptor family in cancer. , 2016, Cancer treatment reviews.

[13]  Z. Bi,et al.  Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3 , 2016, Molecular Biology Reports.

[14]  T. Mohr,et al.  Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma? , 2015, Hepatology.

[15]  T. Tomita,et al.  FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells , 2015, BMC Cancer.

[16]  C. Pirker,et al.  Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. , 2014, Carcinogenesis.

[17]  H. Kocher,et al.  Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma , 2014, Journal of hepatocellular carcinoma.

[18]  Tsung-Ming Chen,et al.  Overexpression of FGF9 in colon cancer cells is mediated by hypoxia-induced translational activation , 2013, Nucleic acids research.

[19]  Min Deng,et al.  miR-26a Suppresses Tumor Growth and Metastasis by Targeting FGF9 in Gastric Cancer , 2013, PloS one.

[20]  R. Chang,et al.  MicroRNA‐140‐5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma , 2013, Hepatology.

[21]  Pascal Furet,et al.  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.

[22]  C. Ellis,et al.  Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells , 2011, Nature Biotechnology.

[23]  T. Mohr,et al.  Up‐regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis , 2011, Hepatology.

[24]  Makoto Taiji,et al.  FGF9 monomer/dimer equilibrium regulates extracellular matrix affinity and tissue diffusion , 2009, Nature Genetics.

[25]  C. Pirker,et al.  New cellular tools reveal complex epithelial–mesenchymal interactions in hepatocarcinogenesis , 2008, British Journal of Cancer.

[26]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[27]  M. Mohammadi,et al.  Crystal Structure of Fibroblast Growth Factor 9 Reveals Regions Implicated in Dimerization and Autoinhibition* , 2001, The Journal of Biological Chemistry.

[28]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[29]  T. Korff.  Three-Dimensional in Vitro Angiogenesis Assays , 2004 .